Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein light chain roadblock-type 1 (DYNLRB1) is a small, non-catalytic accessory subunit of the cytoplasmic dynein 1 motor complex, a multi-protein complex responsible for retrograde transport along microtubules in cells[1][2][3][4]. DYNLRB1 serves as an adaptor, linking specific cargos and regulatory complexes to dynein, and is required for essential cellular processes, including spindle pole integrity during mitosis and long-range organelle and signal transport in neurons[1][2][3]. It is highly conserved and ubiquitously expressed, with knockout or depletion resulting in embryonic lethality and severe neuronal deficits[2]. DYNLRB1 is not an enzyme, receptor, transporter, or ion channel, but its function is crucial for proper dynein-mediated cargo selection and intracellular trafficking across various cell types[1][2][3][4]. It has been implicated in neurodevelopment and possibly neurodegenerative disease due to its essential role in neuronal survival and axonal transport[2]. Key references: - [1] DYNLRB1 maintains mitotic spindle pole integrity and is essential for proper chromosomal segregation. - [2] Conditional knockout models show DYNLRB1 is required for neuronal survival and general dynein-based transport; global knockout is embryonic lethal. - [3] UniProt describes DYNLRB1 as a non-catalytic component of the cytoplasmic dynein complex. - [4] GeneCards highlights its function as a dynein 1 complex accessory protein. There are no known drugs that directly target DYNLRB1, and it is not currently considered a therapeutic target or biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynein light chain roadblock-type 1 (DYNLRB1).